Pipeline

List of Programs

  • Outsourced Clinical Studies

    Code Target Therapeutic Area Basic reserch,
    Drug Discovery    		 Preclinical
    Study    		 Phase 1 Partner
    ADCT-701(LIV-1205 ADC) DLK-1 Oncology / ADC
    		National Cancer Inrtitute

  • In-house developed product★First in class
    ★★World first drug discovery modality moving into clinical phase

    Code Target Therapeutic Area Basic reserch,
    Drug Discovery    		 Preclinical
    Study    		 Phase 1 Status
    ★CBA-1205(ADCC enhanced) DLK-1 Oncology
    		Phase 1
    ★★CBA-1535(Tribody ™) 5T4×CD3
    ×5T4    		 Oncology
    		Phase 1

  • License candidate and drug discovery project★First in class

    　　　　　　　　　　
    Code Target Therapeutic Area Basic reserch,
    Drug Discovery    		 Preclinical
    Study    		 Phase 1 Status
    ★PCDC CDCP1 Oncology
    /ADC
    		Licensing opportunity
    PTRY 5T4×CD3
    ×PD-L1    		 Oncology
    		Data is being obtained for outsourcing
    BMAA SEMA3A Renal and other diseases
    		Licensing opportunity
    LIV-2008/2008b TROP-2 Oncology
    		Licensing opportunity
    PFKR CX3CR1 Autoimmune disease
    		License to Asahi Kasei Pharma
    PXLR CXCXCR1/2/3/5 Oncology
    		Licensing opportunity
    Discovery PJ/
    Drug discovery research     		Undisclosed Oncology, CNS, autoimmune diseases, etc.
    		ー

Details

ADCT-701(LIV-1205 ADC)Outsourced Clinical Studies

ADCT-701 (Humanized anti-DLK1 antibody ADC)

Unmet needs that we should satisfy : Providing therapeutics that are effective for patients who have not seen sufficient efficacy using standard treatment methods for solid tumors, including liver cancer. ADCT-701 is an antibody-drug conjugate of the antibody LIV-1205 developed by Chiome and PBD*. National Cancer Institute (NCI) completed IND submission in the USA, the first dose for neuroendocrine tumor started in July 2024. (*Pyrrolobenzodiazepine : Drug with anti-tumor properties)

CBA-1205(ADCC enhanced)Pre-Outlicensing

CBA-1205（Humanized afucosylated anti-DLK1 antibody)

  • Origin

    A humanized antibody generated by hybridoma technology.

  • Therapeutic
    Area

    Liver cancer, lung cancer, neuroblastoma etc.

  • Expectation

    First-in-class therapeutic antibody targeting intractable cancers

  • Patent

    Granted in Japan, US, Europe, China etc.

Unmet needs that we should satisfy:
Providing new therapeutics for highly malignant tumors without effective therapeutic drugs including hepatocellular carcinoma.

CBA-1535 Pre-Outlicensing

CBA-1535（Humanized anti 5T4xCD3 antibody, multi-specific antibody)

  • Origin

    CBA-1535 is a T-cell engager, trispecific antibody, directed against the 5T4xCD3 tumour antigen, a protein found on many different solid tumours and is thought to contribute to the spread of cancer cells. CBA-1535 recruits the patient’s T-cells killer cells of the immune-system and directs them to attack tumours. This highly targeted approach uses the patient’s own immune system to fight cancer.

  • Therapeutic
    Area

    Malignant mesothelioma, small cell lung cancer, non small cell lung cancer, TNBC etc.

  • Expectation

    First-in-class therapeutic antibody with tri-specific format

  • Patent

    Granted in Japan, UK, US, EU, China etc.

Unmet needs that we should satisfy:
Offer a new treatment option for a disease which has poor prognosis and where there is only few effective treatment.

PCDC Pre-Outlicensing

PCDC（humanized anti-CDCP1 antibody for antibody drug conjugate)

  • Origin

    Humanized anti-CDCP1 antibody discovered by Chiome’s proprietary antibody technologies.

  • Therapeutic
    Area

    Solid tumors (lung, colorectal, pancreatic, breast, ovarian etc.)

  • Expectation

    CDCP1 is a First-in-class therapeutic target highly expressed in broad range of solid tumors, including standard-of-care resistant cases.
    High efficacy and safety expected from binding and toxicological profiles of the antibody.

  • Patent

    Granted in China. Pnding in Japan, US, Europe etc.

PTRY Pre-Outlicensing

PTRY（humanized antibody 5T4/CD3/PD-L1 multi-specific antibodies)

  • Origin

    Therapeutic antibodies for cancer treatment using Tribody™ technology consisting of three binding sites.

  • Therapeutic
    Area

    Malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, Triple Negative Breast Cancer (TNBC) etc.

  • Expectation

    A new study drug for patients who have not responded adequately to standard cancer immunotherapy. It is also expected to be useful in contributing to the healthcare economy by reducing drug prices.
    High efficacy and safety expected from binding and toxicological profiles of the antibody.

  • Patent

    Patent application completed.

    　　　　　　　　

BMAA Pre-Outlicensing

BMAA（Humanized anti-Semphorin3A antibody）

  • Origin

    A humanized antibody generated using the ADLib® System.
    Demonstrated as a selective antibody possessing functional inhibitory activity through collaboration with Professor Yoshio Goshima in Yokohama City University.

  • Therapeutic
    Area

    Renal and other diseases

  • Expectation

    To be applied in a wide range of disease areas including inflammatory and CNS diseases which involve SEMA3A.

  • Patent

    Granted in Japan, US and Europe

LIV-2008/2008bPre-Outlicensing

LIV-2008/2008b（Humanized anti-TROP-2 antibody)

  • Origin

    A humanized antibody generated by hybridoma technology in Chiome

  • Therapeutic
    Area

    Breast cancer (TNBC), lung cancer, colorectal cancer etc.

  • Expectation

    Best-in-class therapeutic antibody targeting breast cancer (TNBC), lung cancer etc.

  • Patent

    Granted in Japan, US, Europe and China.

　　　　　

PFKR Out-Licensed Product

PFKR（humanized anti-CX3CR1 antibody)

  • Origin

    Functional inhibitory antibody of Fractalkine (CX3CL1) receptor and a therapeutic antibody that inhibits disease progression of autoimmune neurological diseases, etc.

  • Therapeutic
    Area

    Secondary Progressive Multiple Sclerosis (SPMS), etc.

  • Expectation

    SPMS is an intractable form of multiple sclerosis and is a disease with a need to develop high safety and effective therapeutic agents. By suppressing cytotoxic Eomes-positive CD4+T cells function which are considered directly related to lesions in SPMS (demyelination, neurodegeneration), expected to inhibit the progression of symptoms.

  • Patent

    Patent application completed.

  • Joint development partner(s)

    National Center of Neurology and Psychiatry

PXLR Pre-Outlicensing

PXLRR(humanized anti-CXCL1/2/3/5 antibody)

  • Origin

    Functional inhibitory antibody for CXCL1/2/3/5, chemoattractant of CXCR2 expressing cell. Cancer therapeutic antibody that improves drug-resistant cancer microenvironment

  • Therapeutic
    Area

    Solid tumors (gastric, breast, ovarian etc.)

  • Expectation

    Cancer cells express CXCL1/2/3/5 and attract immunosuppressor cells that cause the drug-resistant environment. Dosing PXLR antibody will reduce immunosuppressor cells. It is expected to overcome drug-resistance and inhibit the recurrence of cancers.

  • Patent

    Patent application completed.

  • Joint development partner(s)

    Osaka Metropolitan University